Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
T cell–intrinsic VISTA expression promotes resistance to CTLA-4 blockade by restricting CD8+ T cell responses
Cassandra Gilmour, Elizabeth DeLaney, Prerana B. Parthasarathy, Dia Roy, Hieu M. Ta, Amin Zakeri, Paolo Elguera Grandez, Sachin Patnaik, Keman Zhang, Ivan Juric, Rahul Rangan, Zahraa Al-Hilli, Anthony Tufaro, Booki Min, Samuel E. Weinberg, Timothy A. Chan, Natalie L. Silver, Stefanie Avril, Tyler Alban, Li Lily Wang
Cassandra Gilmour, Elizabeth DeLaney, Prerana B. Parthasarathy, Dia Roy, Hieu M. Ta, Amin Zakeri, Paolo Elguera Grandez, Sachin Patnaik, Keman Zhang, Ivan Juric, Rahul Rangan, Zahraa Al-Hilli, Anthony Tufaro, Booki Min, Samuel E. Weinberg, Timothy A. Chan, Natalie L. Silver, Stefanie Avril, Tyler Alban, Li Lily Wang
View: Text | PDF
Research Article Immunology Oncology

T cell–intrinsic VISTA expression promotes resistance to CTLA-4 blockade by restricting CD8+ T cell responses

  • Text
  • PDF
Abstract

V-domain immunoglobulin suppressor of T cell activation (VISTA) is an immune checkpoint protein that impairs antitumor T cell responses. While broadly expressed on myeloid cells and T cells, the specific contribution of T cell–intrinsic VISTA to antitumor immunity remains undefined. This study investigated the phenotypic and functional consequences of T cell–specific VISTA deletion in tumor-specific CD8+ T cells. Single-cell transcriptomic analysis, TCR repertoire profiling, and flow cytometry revealed that loss of T cell–intrinsic VISTA enhanced early priming and short-term expansion of CD8+ T cells, yet this initial advantage failed to confer durable tumor control. Persistent dysfunction in VISTA-deficient T cells was in part driven by trans-VISTA on myeloid cells, while CTLA-4 upregulation further constrained T cell responses. T cell–intrinsic VISTA deficiency cooperated with CTLA-4 blockade to improve T cell survival and broaden TCR repertoire diversity, resulting in more robust tumor regression than CTLA-4 inhibition alone. A transcriptional signature enriched in VISTA-deficient cytotoxic T cells correlated with favorable outcomes in cancer patients treated with existing immune checkpoint inhibitors. These findings collectively define T cell–intrinsic mechanisms by which VISTA enforces T cell dysfunction and underscore its potential as both a therapeutic target and a biomarker of resistance to current immunotherapies.

Authors

Cassandra Gilmour, Elizabeth DeLaney, Prerana B. Parthasarathy, Dia Roy, Hieu M. Ta, Amin Zakeri, Paolo Elguera Grandez, Sachin Patnaik, Keman Zhang, Ivan Juric, Rahul Rangan, Zahraa Al-Hilli, Anthony Tufaro, Booki Min, Samuel E. Weinberg, Timothy A. Chan, Natalie L. Silver, Stefanie Avril, Tyler Alban, Li Lily Wang

×

Figure 4

T cell–intrinsic VISTA deficiency synergized with CTLA-4 blockade to boost antitumor T cell responses.

Options: View larger image (or click on image) Download as PowerPoint
T cell–intrinsic VISTA deficiency synergized with CTLA-4 blockade to boo...
(A) CTLA-4 expression on tumor-infiltrating OT1 T cells adoptively transferred into mice bearing B16.OVA tumors. N = 3. (B) WT and Vsir–/– CD8+ T cells were activated with anti-CD3 in the presence of anti–CTLA-4 antibody or isotype IgG. Expanded live T cells after 72 hours were enumerated. N = 4. (C and D) VISTA-KO mice (Vsirfl/fl CD4Cre, N = 22) and WT controls (N = 18) bearing B16bl6 tumors were treated with a peptide vaccine and anti–CTLA-4 antibodies. Tumor progression is shown in C. Mice survival up to 60 days is shown in D. (E) Tumor-free mice were rechallenged with melanoma cells and monitored for tumor growth. N = 5 (naive WT), 11 (tumor-free Vsirfl/fl CD4Cre), and 4 (naive Vsirfl/fl CD4Cre). (F–M) CD8+ TILs were analyzed on day 16 after treatment with the vaccine and anti-CTLA4 antibodies. (F) Numbers of CD45+ TILs. (G) Frequencies of CD8+ TILs recognized by TRP2-specific dextramer. N = 7 for F and G. (H) Frequencies of dead CD8+ TILs. N = 10 (Vsirfl/fl), 9 (Vsirfl/fl CD4Cre). (I) Frequencies of quiescent CD8+ TILs (TCF1+CD62L+PD-1–). N = 6. (J) Frequencies of BrdU-incorporating CD8+ TILs. N = 4. (K) Expression of granzyme B (N = 5). (L) Expression of IFN-γ and TNF-α. N = 6 (Vsirfl/fl) and 4 (Vsirfl/fl CD4Cre). (M) Representative flow plots of CD8+ TILs stained with MG and MDR dyes and frequencies of MG+MDRlo cells. (N) WT and Vsir–/– OT1 T cells (N = 7) were cotransferred at a 1:1 ratio into mice bearing B16.OVA tumors and analyzed after 9 days. Frequencies of MG+MDRlo OT1 TILs are shown. For M, N = 10 (Vsirfl/fl) and 15 (Vsirfl/fl CD4Cre). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Significance was assessed using unpaired 2-tailed Student’s t test (A and F–N), 1-way ANOVA (B), 2-way ANOVA with a Šidák’s multiple-comparison test (C), or log-rank Mantel-Cox test (D and E). Data are presented as mean ± SEM. All experiments were repeated 2–3 times.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts